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Abnormal expression of annexin A2 contributes to metastasis and inﬁltration of cancer cells. To elucidate the cause of abnormal expres-
sion of annexin A2, Western blotting, immunoproteomics and immunohistochemical staining were performed to analyze diﬀerentially
ubiquitinated proteins between fresh breast cancer tissue and its adjacent normal breast tissue from ﬁve female volunteers. We detected
an ubiquitinated protein that was up-regulated in the cancer tissue, which was further identiﬁed as annexin A2 by mass spectrometry.
These results suggest that abnormal ubiquitination and/or degradation of annexin A2 may lead to presence of annexin A2 at high level,
which may further promote metastasis and inﬁltration of the breast cancer cells.
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Annexin A2 is a 36 kDa peripheral membrane protein that
belongs to the annexin family of Ca2+ and phospholipid-
binding proteins, which plays a role in membrane organiza-
tion and dynamics in particular along the endocytic
pathway [1]. Up-regulation of annexin A2 has been
observed in cancer cells, along with high expression of
plasminogen that is activated by annexin A2, which might
contribute to hemorrhage in the tissue and metastasis of
cancer cells [2]. Abnormal expression of annexin A2 was
found in a variety of tumors such as pancreatic cancer,
prostate carcinoma, hepatocellular carcinoma, oral squa-
mous cell carcinoma and breast cancer [3–8]. Over-expres-
sion of annexin A2 is associated with tumor invasion and
progression [9].
Ubiquitin-dependent proteolysis mediates selective deg-
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[10–12]. It has been reported that regulation of annexin
A2 is associated with ubiquitination in endothelial cells
[13]. In breast cancer tissue, we previously observed abnor-
mal expression of some components of the ubiquitin pro-
teasome system [14], and the results also indicated that
the general ubiquitination proﬁling was changed in breast
cancer. To understand whether abnormal expression of
annexin A2 is correlated to abnormal ubiquitination in
breast cancer tissue, we investigated diﬀerential protein
ubiquitination between breast cancer and the adjacent
normal tissue, using two-dimensional gel electrophoresis
(2-DE), immunoblotting, mass spectrometry (MALDI-
TOF-TOF MS) and immunohistochemistry.Results
To examine the protein ubiquitination in cancer tissue and
the adjacent normal tissue, we prepared protein samples
from the two tissues and performed Western blotting usingcademy of Sciences and Genetics Society of China. Published by Elsevier
Figure 1 Diﬀerential ubiquitination between breast cancer tissue and the
adjacent normal tissue using SDS–PAGE
Western blotting was performed on protein samples from breast cancer
tissue (Ca) and adjacent normal tissue (No) using anti-ubiquitin antibody.
The molecular weight of the band indicated by& is around 45 kDa.
Figure 2 Diﬀerentially-ubiquitinated spots between breast cancer tissue and
the adjacent normal tissue using 2-DE
Protein from breast cancer tissue (Ca) and adjacent normal tissue (No)
was separated using 2-DE (IPG 7 cm, pH3–10, nonlinear). Western
blotting was performed using anti-ubiquitin antibody. The molecular
weight of the spot indicated by! is around 45 kDa.
Figure 3 2-DE gel spots subjected to MALDI-TOF-TOF MS
Two spots (a and b) identiﬁed as diﬀerentially-ubiquitinated according to
Figure 2 and an adjacent spot (c) were cut from 2-DE gels stained with
Coomassie Brilliant Blue R-250 and subjected to MALDI-TOF-TOF MS.
All of them were identiﬁed as annexin A2.
154 Genomics Proteomics Bioinformatics 10 (2012) 153–157an anti-ubiquitin antibody after SDS–PAGE. As shown in
Figure 1, diﬀerent patterns were revealed for these two tis-
sues. For example, protein of 66 kDa (serum albumin) was
heavily ubiquitinated in cancer tissue, compared to the nor-
mal tissue. Interestingly, a band with molecular weight
approximately 45 kDa was easily detected in cancer tissue
sample by immunoblotting and protein staining with Coo-
massie Brilliant Blue R-250, while it was barely seen in
sample from adjacent normal tissue.
We next ran 2-D electrophoresis (2-DE) of these two
samples and performed immunoblotting with an anti-ubiq-
uitin antibody. As shown in Figure 2, we detected a broad
dense spot of molecular weight approximately 45kD in
protein samples from cancer tissues. The intensity of this
spot was more than three fold as high as that from adjacent
normal tissues according to PDQuest software 7.1, indicat-
ing a signiﬁcant diﬀerence.
The two spots (a and b), which corresponded to the sin-
gle spot with diﬀerential ubiquitination in Figure 2, were
excised from the duplicate gel and subjected to MALDI-
TOF-TOF mass spectrometry (MS) (Figure 3). To avoid
bias of position from membrane to gel, an adjacent spot
(c) was also excised for MS analysis from the duplicate
gel stained with Coomassie Brilliant Blue R-250. The
results showed that all of these three spot were identiﬁed
as annexin A2 (Table 1).To further validate the expression of annexin A2 in can-
cer tissue, we did immunohistochemical staining using
Table 1 Identiﬁcation of protein spots by MALDI-TOF-TOF MS analysis
Protein spot Protein name Accession No. MW (Da) Protein PI No. of unique peptides matched
a ANXA2 protein gi|73909156 40502.8 8.41 13
b Chain A, Annexin A2 gi|56966699 38637.8 6.92 13
c Annexin A2 gi|16306978 38593.8 7.57 14
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cancer cells from all patients was positive for annexin A2
staining while that of cells from adjacent normal tissue
was negative (Figure 4).
Discussion
The ubiquitin proteasome pathway degrades many growth
factors, oncogene proteins (c-myc, c-fos, c-jun and src) and
cancer suppressor proteins (p53 and p27), and is therefore
associated with cancer transformation, tumor progress,
immune monitoring escape and tumor drug resistance
[16,17]. Metastasis and inﬁltration are important biological
characteristics of cancer cells, and overexpression of
annexin A2 contributes to these processes in breast cancer
cells [9].
In this study, we examined ubiquitination of total pro-
teins from human fresh breast cancer tissue and its adjacent
normal tissue with western blotting using anti-ubiquitin
antibody, and observed that there was a diﬀerentially-ubiq-
uitinated protein of approximately 45kD. 2-DE accompa-
nied by western blotting and MALDI-TOF-TOF MS was
used to identify diﬀerential spots.
We previously reported overexpression of genes and
proteins of ubiquitin speciﬁc peptidases and proteasome
subunits in breast cancer tissue, which suggested that func-
tions of the ubiquitin proteasome pathway might be altered
[14]. Here, by immunoproteomics and MALDI-TOF-TOF
MS, we ﬁnd that annexin A2 is ubiquitinated in human
breast cancer tissue, suggesting that regulation of annexin
A2 might involve the ubiquitin proteasome pathway in this
tissue. By immunohistochemistry, we veriﬁed overexpres-
sion of annexin A2 in breast cancer tissue. The results indi-
cated that annexin A2 in breast cancer was overexpressed
and abnormally ubiquitinated.Figure 4 Immunohistochemical staining of annexin A2 in tissue sections
Paraﬃn sections of breast cancer tissue (Ca) and the adjacent normal tissue (N
antibody (DAB coloring, 200 folds).Regulation of annexin A2 is associated with ubiquitina-
tion in endothelial cells [13]. Polyubiquitinated proteins are
generally degraded by 26S proteasome, while monoubiqui-
tination is a modulating signal which causes the target pro-
tein to alter its activity, positioning or structure, and thus
regulating the endocytosis pathway, histone modiﬁcation,
gene transcription and protein nuclear localization [18].
Annexin A1, another member of annexin family, was
reported to be modiﬁed by ubiquitin and SUMO (small
ubiquitin-like modiﬁer) [19]. Mono-ubiquitinated Annexin
A1 has higher aﬃnity for damaged DNA, while SUMOy-
lated annexin A1 functioned in proliferation-diﬀerentiation
[19]. Annexin A2 was ubiquitinated in the breast cancer tis-
sue, which might be explained in two ways: (i) Annexin A2
is attached with poly ubiquitination (a and b spots, Fig-
ure 3), so annexin A2 might be degraded by 26S protea-
some, which may explain much higher spot intensity
detected in cancer sample (Figure 2). (ii) Annexin A2 was
regulated by monoubiquitination (c spot, Figure 3) with
its non-degradation function, such as ubiquitination-regu-
lated genetic transcription and signal transduction [20,21],
and the results could explain that this position of c spot
was not obviously detected in immunoblotting by ubiquitin
antibody (Figure 2). Therefore, there could be two kinds of
ubiquitination, including poly and mono ubiquitination.
Further investigations are needed to ﬁgure out the status
of ubiquitination for annexin A2 and their association with
its upregulated expression in breast cancer.
Ubiquitination of proteins is a very complicated protein
modiﬁcation. Many proteins in human are regulated to a
high or low level by ubiquitination. Abnormal protein lev-
els caused by altered protein ubiquitination lead to occur-
rence of disease [22]. It has been reported that the
ubiquitin proteasome system was not activated in a well-
characterized cell culture based breast cancer model systemo) were staining by immunohistochemical method with anti-annexin A2
156 Genomics Proteomics Bioinformatics 10 (2012) 153–157[10]. To avoid controversy, we used fresh human breast
cancer tissue to study ubiquitination of annexin A2, as
ubiquitin activity is detected in human breast cancer cells.
Overexpression of annexin A2 may be associated with
abnormal ubiquitination, but the mechanism is much more
complicated, including its degradation and/or non-degra-
dation function. Abnormal ubiquitination might be associ-
ated with higher level of annexin A2, and contribute to
metastasis and inﬁltration of breast cancer cells. Therefore,
annexin A2 could be a candidate marker for treatment of
breast cancer.Materials and methods
Tissue samples
Fresh breast cancer tissue and its adjacent normal tissue
were obtained after surgical operation (mastectomy) from
ﬁve female patients, aged 31–58 years, hospitalized in the
Aﬃliated Hospital of North Sichuan Medical College,
who suﬀered from breast cancer (T1N1M0 for 2 patients,
T1N2M0 for 1 patient and T2N2M0 for 2 patients). Some
samples were immediately frozen at –150 C (Super Low
Temperature Icebox, REVCO, CT, USA) and used for
protein extraction, and some were used for pathological
and immunohistochemical analysis. Cancer tissue for pro-
tein extraction was non-necrotic, non-purulent and non-
hemorrhagic. The type of cancer from all of 5 patients
was later veriﬁed with pathology as inﬁltrating ductal car-
cinoma (14). The research was approved by the Ethics
Committee of North Sichuan Medical College and all
patients signed the written informed consent to participate
in the study.
Protein extraction
Protein was extracted using ReadyPreTM Protein Extrac-
tion Kit (total protein) (Bio-Rad, CA, USA), and protein
samples were stored in aliquots of 200 lL at 80 C. Con-
centration of total proteins was measured with Bio-Rad
RC DC Protein Assay.
Western blotting analysis
Firstly, 35 lg of total protein sample of breast cancer or
normal tissue was used for electrophoresis in 12% SDS–
PAGE gel. Then the protein was transferred to nitrocellu-
lose (0.45 lm; Bio-Rad) in transfer buﬀer (39 mM glycine,
48 mM Tris, 0.037% SDS, 20% methanol) with electroblot-
ting (using Mini-Trans-Blot electrophoretic transfer cell by
Bio-Rad) at 30 V overnight. Immunodetection was carried
out as previously described [15] using the anti-ubiquitin
antibody (Chemicon, CA, USA) as the primary antibody.
The goat anti-rabbit second antibody conjugated with
alkaline phosphatase was detected colorimetrically with
NBT/BCIP (KPL, USA).Immunoproteomics
Protein samples of breast cancer and adjacent normal tis-
sues from each patient were separately used for 2-DE.
Duplicate gels were run for diﬀerent read-outs. Since the
protein sample contained substances such as salts, nucleic
acids and lipids that are known to interfere with isoelectric
focusing (IEF), such substances were removed using the
ReadyPreTM Cleanup Kit (Bio-Rad). With this procedure,
the concentration of total proteins is increased. So the con-
centration was measured again prior to IEF.
The ﬁrst-dimension isoelectric focusing (IEF) was per-
formed with precast IPG strips (pH 3.0–10.0, nonlinear
pH IPG, 7 cm, Bio-Rad) using a focusing tray (Bio-Rad).
The loading volume of protein sample was 120 lL (the
loading content of protein sample of 300 lg stained with
Coomassie Brilliant Blue R-250 in every gel), and IEF
was carried out at 20 C using 50 lA/strip. The strips were
equilibrated after IEF. The equilibrated strips were placed
on top of a 12% SDS–PAGE gel prepared and sealed in
place with 0.5% low-melt agarose (Sigma, CA, USA).
The SDS–PAGE was performed with MINI PROTEAN
IITM (Bio-Rad).
After 2-DE, 1 pair of gels (one for normal tissue and one
for cancer tissue) were analyzed by Western blotting using
anti-ubiquitin antibody (Chemicon) as the primary anti-
body. The other pair were stained with Coomassie Brilliant
Blue R-250 (Amresco, NY, USA) and scanned with
UMAXpowerlook 1120 (UMAX, Taipei, Taiwan) to
obtain diﬀerentially-ubiquitinated protein spots using
PDQuest software (7.1). The pilot experiments for repeat-
ability test from ten Coomassie staining gels showed that
the spot positional deviation was 1.469 ± 0.238 mm for
IEF and 1.016 ± 0.197 mm for SDS–PAGE while the spot
volume deviation was 19.6 ± 11.1% with PDQuest soft-
ware 7.
After Western blotting, we aligned the membrane with
the duplicate gels stained with Coomassie Brilliant Blue
R-250. The identiﬁed diﬀerentially-ubiquitinated protein
spots with high repeatability and one adjacent spot were
located and excised from the duplicate gels and then iden-
tiﬁed using MALDI-TOF-TOF MS. MS analysis of pep-
tides was performed on an ABI 4700 TOF-TOF
Proteomics (Applied Biosystems). The UV laser was oper-
ated at a 200 Hz repetition rate with wavelength of 355 nm.
The accelerated voltage was operated at 20 kV, and mass
resolution was maximized at 1500 Da. Myoglobin digested
with trypsin was used to calibrate the mass instrument with
an internal calibration mode. All spectra of samples
acquired were processed using 4700 ExploreTM Software
(Applied Biosystems) in a default mode. The data were
searched by GPS Explorer V3.6 with the search engine
MASCOT 2.1. The search parameters were as follows:
the database NCBInr (NCBI2009: 9874297 sequences,
3367796496 residues), taxonomy Homo Sapiens [human],
protein molecular mass ranged from 700 to 3000 Da, tryp-
sin digest with one missing cleavage, MS tolerance was set
Deng S et al / Abnormal Ubiquitination of Annexin A2 in Breast Cancer 157at 0.3 Da, and MS/MS tolerance at 0.4 Da. Data were pro-
cessed and analyzed in Fudan University [14]. Proteins
with scores >59 or best ion scores (MS/MS) >30 were con-
sidered as signiﬁcant (P < 0.05).
Immunohistochemical staining
Tissue samples were cut into small blocks (4–6 mm in
length) and ﬁxed in 10% formalin solution. After dehydra-
tion in ethanol and clearing in xylene, tissue blocks were
embedded in paraﬃn and sectioned at 5 lm in thickness.
Immunohistochemical staining was performed using an
UltrasensitiveTM SP Kit (MAIXIN-BIO, Fuzhou, China)
with the primary antibody (dilution 1:50) of anti-annexin
A2 (Abcam, Cambridge, UK). The rabbit anti-rat second
antibody conjugated with horse radish peroxidase (HRP)
was detected by DAB coloring (AR1022, MAIXIN-BIO).
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